PROGNOSTIC IMPACT OF CD34 EXPRESSION IN PAEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA

Authors

  • Afshan Noor Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan
  • Manzar Bozdar Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan
  • Hamid Saeed Malik Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan
  • Muhammad Omair Riaz Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan
  • Rafia Mahmood Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan
  • Nighat Seema Department of Forensic Medicine, Ayub Medical College, Abbottabad-Pakistan

DOI:

https://doi.org/10.55519/JAMC-S4-14073

Keywords:

Acute lymphoblastic leukemia (ALL); CD34 expression; paediatric; remission status

Abstract

Background: Acute lymphoblastic leukaemia (ALL) affects adults as well as children. Malignant transformation and proliferation occur in lymphoid progenitor cells found in bone marrow, blood, and extra-medullary locations. Precursor B-cell types account for the majority of ALL cases. Objective was to measure the expression of CD34 positive cells as a prognosis-related marker in paediatric Acute Lymphoblastic Leukaemia (ALL). It was a prospective cohort study, conducted at the Armed Forces Institute of Pathology, Rawalpindi, from July 2022 till July 2023. Methods: This study investigates the expression of CD34, a marker associated with hematopoietic stem and progenitor cells, in paediatric ALL and its correlation with clinical outcomes. Our study included 122 children aged 18 years or younger, newly diagnosed with ALL. Patients were diagnosed on complete blood counts and initial bone marrow examination, followed by flow cytometry. Essential molecular and cytogenetic studies were also carried out, followed by “day 29” induction marrow to assess the remission status of the patients under treatment protocols. CD34 expression was measured by flow cytometry and correlated with the clinic-haematological parameters of the patients for identification of risk groups. Results: The study comprised of 78 (63.9%) males and 44 (36.1%) females. Overall, 79% of patients showed CD34 expression while its expression was absent in 21% patients. CD34 expression was correlated with higher total leucocyte count, increased peripheral blood blast percentage, decreased platelet count and increased transfusion dependency. Minimal residual disease status was significantly better in CD34 negative patients as compared to CD34 positive patients. Conclusion: Expression of CD34 is an adverse prognostic marker in ALL patients and the presence of this antigen affects the clinical outcome of these patients.

Author Biography

Afshan Noor, Department of Haematology, Armed Forces Institute of Pathology, National University of Medical Sciences, Rawalpindi-Pakistan

Postgraduate Trainee , Department of Haematology, Armed Forces Institute of Pathology, National Unversity Of Medical Sciences, Rawalpindi.

References

1. Daltveit DS, Morgan E, Colombet M, Steliarova-Foucher E, Bendahhou K, Marcos-Gragera R, et al. Global patterns of leukaemia by subtype, age, and sex in 185 countries in 2022. Leukaemia 2025;39(2):412–9.

2. Sheykhhasan M, Manoochehri H, Dama P. Use of CAR T-cell for acute lymphoblastic leukaemia (ALL) treatment: a review study. Cancer Gene Ther 2022;29(8):1080–96.

3. Chang JH, Poppe MM, Hua CH, Marcus KJ, Esiashvili N. Acute lymphoblastic leukaemia. Pediatr Blood Cancer 2021;68(Suppl 2):e28371.

4. Oldenburg M, Rüchel N, Janssen S, Borkhardt A, Gössling KL. The microbiome in childhood acute lymphoblastic leukaemia. Cancers (Basel) 2021;13(19):4947.

5. Malczewska M, Kośmider K, Bednarz K, Ostapińska K, Lejman M, Zawitkowska J. Recent advances in treatment options for childhood acute lymphoblastic leukaemia. Cancers (Basel) 2022;14(8):2021.

6. Rezaei MS, Esfandiari N, Refoua S, Shamaei M. Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukaemia: lessons from regional variation. Iran J Pathol 2020;15(1):1.

7. Gupta R, Garg N, Kotru M, Kumar D, Pathak R. Immunophenotypic characteristics of T lineage acute lymphoblastic leukaemia: absence of immaturity markers-TdT, CD34 and HLADR is not uncommon. Am J Blood Res 2022;12(1):1.

8. Wang Y, Mo X, Cheng Y, Chen Y, Lv M, Wang F, et al. Effects of CD34+ cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease. Int J Lab Hematol 2023;45(1):72–81.

9. Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. T cell acute lymphoblastic leukaemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev 2018;32(1):36–51.

10. Jaafar FH, Kadhom AE. Expression of CD45, CD34, CD10, and human leukocyte antigen-DR in acute lymphoblastic leukaemia. Iraq J Hematol 2018;7(1):14–9.

11. Modvig S, Wernersson R, Øbro NF, Olsen LR, Christensen C, Rosthøj S, et al. High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion. Mol Oncol 2022;16(10):2015–30.

12. Vardiman J, Thiele J, Arber D. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rationale and important changes. Blood 2009;114(5):937–51.

13. Shaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013). Basel, Switzerland: S. Karger, 2013.

14. Gholamreza B, Marzeih N. Frequency of cytogenetic findings and its effect on the outcome of paediatric acute lymphoblastic leukaemia. Med Arch 2019;73(5):311.

15. Huang FL, Liao EC, Li CL, Yen CY, Yu SJ. Pathogenesis of pediatric B-cell acute lymphoblastic leukaemia: Molecular pathways and disease treatments. Oncol Lett 2020;20(1):448–54

16. Zhao J, Wang Y, Zhou M, Gao J, Yuan Y. The prognostic effect on childhood acute lymphoblastic leukaemia of CD34+ CD38− expressed in leukaemia cells. Hematology 2022;27(1):706–13.

17. Sultan S, Irfan SM, Parveen S, Mustafa S. Acute lymphoblastic leukaemia in adults-an analysis of 51 cases from a tertiary care center in Pakistan. Asian Pac J Cancer Prev 2016;17(4):2307–9.

18. Ahmad I, Ghafoor T, Ullah A, Naz S, Tahir M, Ahmed S, et al. Pediatric Acute Lymphoblastic Leukaemia: Clinical Characteristics, Treatment Outcomes, and Prognostic Factors: 10 Years' Experience From a Low-and Middle-Income Country. JCO Glob Oncol 2023;9:e2200288.

19. Afzal M, Sharma A, Sah AK, Chahal A. Structural and functional alterations in hematological parameters among individuals at clinically high risk for acute lymphocytic leukaemia. Iraq J Hematol 2024:13(2):159–69.

20. Yin T, Han J, Hao J, Yu H, Qiu Y, Xu J, et al. Clinical characteristics and risk factors of acute lymphoblastic leukaemia in children with severe infection during maintenance treatment. Cancer Med 2023;12(19):19372–82.

21. Shah MA, Ahmad U, Mahmood MT, Ahmad AH, Bakar MA. Frequency of CD34 and CD10 expression in adolescent and young adult patients having precursor B-cell acute lymphoblastic leukaemia and its correlation with clinical outcomes: A single-center study. Cureus 2022;14(1):21261.

22. Gao C, Liu SG, Yue ZX, Liu Y, Liang J, Li J, et al. Clinical-biological characteristics and treatment outcomes of pediatric pro-B ALL patients enrolled in BCH-2003 and CCLG-2008 protocol: a study of 121 Chinese children. Cancer Cell Int 2019;19:1–9.

23. Kawasaki Y, Takahashi Y, Kobayashi Y. Clinical significance of CD34 expression in pediatric B-acute lymphoblastic leukaemia: A retrospective study. Leuk Res 2023;121:106964.

24. Kim Y, Lee J, Lim K. Clinical significance of CD34 positivity in pediatric patients with B-cell acute lymphoblastic leukaemia. Pediatr Blood Cancer 2023;70(2):29858.

25. Huang J, Chen Z, Wang Y. The association of hematological parameters and clinical features in pediatric B-ALL: A single center experience. Front Oncol 2023;13:1028405.

26. Liang H, Zhang S, Chen J. CD34 as a potential biomarker for prognostic evaluation of pediatric B-ALL patients. Eur J Haematol 2023;110(4):345-354.

27. Ebinger M, Witte KE, Ahlers J, Schäfer I, André M, Kerst G, et al. High frequency of immature cells at diagnosis predicts high minimal residual disease level in childhood acute lymphoblastic leukaemia. Leuk Res 2010;34(9):1139–42.

28. Attia D, Younes R, Elhaj N. Predictive role of CD34 and molecular markers in pediatric acute lymphoblastic leukaemia in the Middle East. Hematol Oncol 2020;38(5):71–6.

29. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukaemia. N Engl J Med 2012;366(15):1371–81.

30. Al-Kubayasi AS, Ibraheem AJ, Al-Rudaini RS. Evaluation of CD34 expression in pediatric acute lymphoblastic leukaemia: A cross-sectional study on its correlation with clinical outcomes at central teaching hospital of pediatrics, Baghdad. Int J Oncol 2024;6(1):1–5.

31. Khaled MA, Hamdy N, Mahran AM. Correlation of CD34 positivity with clinical features in children with acute lymphoblastic leukaemia. Blood Cells Mol Dis 2023;93:102547.

32. Shah A, Wadhwa S, Bhatia R. Analyzing CD34 positivity as a prognostic marker in B-cell acute lymphoblastic leukaemia. Leuk Lymphoma 2023;64(1):213–21.

33. Parker H, Smith J, Davis M. The role of CD34 in the disease trajectory of pediatric leukaemia: Implications for prognosis and treatment. Clin Cancer Res 2023;29(5):1038–48.

Downloads

Published

2024-12-16

How to Cite

1.
Noor A, Manzar Bozdar, Malik HS, Riaz MO, Mahmood R, Nighat Seema. PROGNOSTIC IMPACT OF CD34 EXPRESSION IN PAEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIA. J Ayub Med Coll Abbottabad [Internet]. 2024 Dec. 16 [cited 2025 May 9];36(4 (Suppl 1):963-9. Available from: https://jamc.ayubmed.edu.pk/index.php/jamc/article/view/14073

Issue

Vol. 36 No. 4 (Suppl 1) (2024): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2024 Afshan Noor, Manzar Bozdar, Hamid Saeed Malik, Muhammad Omair Riaz, Rafia Mahmood, Nighat Seema

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.